Archit Organosys Withdraws Preferential Share Swap For Archit Life Science Acquisition

Board withdrew items 8-10 from 30 Sep AGM notice to restructure: authorised capital hike, acquisition of 1,36,24,172 shares (67.44%) of Archit Life Science, and preferential allotment. Puts the central Archit Life Science consolidation on hold; deal awaited shareholder and exchange approval and is now off the AGM vote, framed as restructuring. No immediate dilution or capital change; revised terms, timeline and valuation undisclosed; related-party loan exposure and approval path remain overhangs.